PubRank

Haval Shirwan

Author PubWeight™ 40.95‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol 2007 1.48
2 CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 2007 1.48
3 Longitudinal tracking of recipient macrophages in a rat chronic cardiac allograft rejection model with noninvasive magnetic resonance imaging using micrometer-sized paramagnetic iron oxide particles. Circulation 2008 1.38
4 Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res 2009 1.26
5 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res 2010 1.21
6 Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs 2007 1.19
7 Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 2002 1.19
8 A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine 2009 1.09
9 Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 2004 1.06
10 Fragmented sleep accelerates tumor growth and progression through recruitment of tumor-associated macrophages and TLR4 signaling. Cancer Res 2014 1.05
11 SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ. PLoS One 2012 0.99
12 Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein. J Immunol 2008 0.97
13 Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 2006 0.95
14 Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. PLoS One 2012 0.95
15 CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models. PLoS One 2013 0.93
16 A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model. Mol Immunol 2007 0.90
17 Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation 2003 0.89
18 Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors. Stem Cells 2007 0.89
19 Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. Exp Hematol 2007 0.89
20 Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon. Exp Mol Pathol 2006 0.88
21 Tolerance to rat heart grafts induced by intrathymic immunomodulation is mediated by indirect recognition primed CD4+CD25+ Treg cells. Transplantation 2005 0.87
22 Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice. J Autoimmun 2011 0.86
23 Prophylactic fenbendazole therapy does not affect the incidence and onset of type 1 diabetes in non-obese diabetic mice. Int Immunol 2006 0.86
24 Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. J Immunol 2011 0.85
25 Is durable macrochimerism key to achieving clinical transplantation tolerance? Curr Opin Organ Transplant 2011 0.85
26 Predominant expression of the Th2 response in chronic cardiac allograft rejection. Transpl Int 2003 0.85
27 SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines. Expert Rev Vaccines 2014 0.85
28 SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine 2010 0.84
29 Tumor necrosis factor receptors support murine hematopoietic progenitor function in the early stages of engraftment. Stem Cells 2010 0.83
30 Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions. Stem Cells 2007 0.82
31 Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo. Hum Gene Ther 2006 0.82
32 The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation. Bioessays 2006 0.81
33 A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Res 2003 0.81
34 Effector and naturally occurring regulatory T cells display no abnormalities in activation induced cell death in NOD mice. PLoS One 2011 0.80
35 ProtEx technology for the generation of novel therapeutic cancer vaccines. Exp Mol Pathol 2009 0.79
36 Killer Treg cells ameliorate inflammatory insulitis in non-obese diabetic mice through local and systemic immunomodulation. Int Immunol 2013 0.79
37 Novel technologies to engineer graft for tolerance induction. Curr Opin Organ Transplant 2016 0.78
38 Blockade of indirect recognition mediated by CD4+ T cells leads to prolonged cardiac xenograft survival. Xenotransplantation 2004 0.78
39 Cardiac allograft acceptance after localized bone marrow transplantation by isolated limb perfusion in nonmyeloablated recipients. Stem Cells 2003 0.78
40 Chronic heart allograft rejection in rats demonstrates a dynamic interplay between IFN-gamma and IL-10 producing T cells. Transpl Immunol 2004 0.78
41 Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease. Exp Hematol 2013 0.78
42 Predominant expression of Th2 cytokines and interferon-gamma in xenogeneic cardiac grafts undergoing acute vascular rejection. Transplantation 2003 0.76
43 ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation. Ann N Y Acad Sci 2005 0.76
44 Characterization of adhesion and viability of early seeding hematopoietic cells in the host bone marrow in vivo and in situ. Exp Hematol 2003 0.76
45 [Allograft tolerance induced by FasL chimeric protein decorated donor splenocytes]. Zhonghua Wai Ke Za Zhi 2010 0.75